Affiliation:
1. The Liposome Company, Inc., Princeton, New Jersey 08540, USA.
Abstract
Amphotericin B lipid complex (ABLC) shows reduced toxicity relative to that of amphotericin B deoxycholate (AmB-d) while maintaining antifungal activity. Rat blood or plasma was spiked with ABLC in vitro. Released amphotericin B was separated from the parent material by centrifugation. At early times (0 to 15 min) most (approximately 90%) of the amphotericin B was complexed. The amount of released amphotericin B increased gradually in a time- and temperature-dependent fashion. The released amphotericin B was associated with plasma lipoprotein and nonlipoprotein proteins. The area under the concentration-time curve from 0 to 24 h for total amphotericin B in whole blood of rats given a single intravenous bolus dose of 1 mg of ABLC per kg of body weight was fourfold lower than that in rats given 1 mg of AmB-d per kg. The complexed amphotericin B was rapidly removed from the circulation and was distributed to the tissues in these rats. Other rats were treated intravenously with ABLC (10 mg/kg/day) or AmB-d (0.5 mg/kg/day) daily for 15 days. Blood was collected at 15 and 180 min after administration of the last dose. The total levels of amphotericin B in the blood of the group given ABLC were about three to five times those in the group given AmB-d, and the concentration of released, protein-bound amphotericin B in the plasma of the group given ABLC was about one to two times that observed for the group given AmB-d, despite the 20-fold difference in dose. The relative protein distribution of amphotericin B in plasma was similar after ABLC or AmB-d administration under these steady-state conditions in vivo. The rapid uptake of complexed amphotericin B by tissues and the very low levels of circulating protein-bound amphotericin B in plasma after the administration of ABLC may explain, in part, the reduced toxicity and enhanced therapeutic index of this preparation.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference25 articles.
1. Anaissie E. J. M. White O. Uzun C. Singer G. P. Bodey D. Matzke N. Azarnia and G. Lopez-Berestein. 1995. Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective randomized multicenter trial abstr LM21 p. 330. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
2. Inhibition of interaction between lipoproteins and amphotericin B by some delivery systems;Barwicz J.;Biochem. Biophys. Res. Commun.,1991
3. Bennett J. E. 1976. Amphotericin B binding to serum betalipoprotein p. 107-109. In K. Iwata (ed.) Recent advances in medical and veterinary mycology. University of Tokyo Press Tokyo Japan.
4. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance;Block E. R.;Ann. Intern. Med.,1974
5. Interaction of plasma proteins and lipoproteins with amphotericin B;Brajtburg J.;J. Infect. Dis.,1984
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献